AvalehtPRRUF • OTCMKTS
add
Immutep Ltd
Viimane sulgemishind
0,18 $
Aasta vahemik
0,17 $ - 0,28 $
Turuväärtus
292,16 mln USD
Keskmine maht
500,00
P/E suhe
-
Dividendimäär
-
Põhibörs
ASX
Börsiuudised
Investor's Business Daily
2 tunni eest
Tech Futures Rise As AI Giant Eyes $1 Tril; Tesla Run Continues
0,13%
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (AUD) | dets 2023info | Y/Y muutus |
|---|---|---|
Käive | 1,06 mln | 25,23% |
Põhitegevusega seonduv kulu | 2,40 mln | 16,20% |
Puhastulu | −10,61 mln | −2,93% |
Puhaskasumimarginaal | −1,01 tuh | 17,80% |
Puhaskasum aktsia kohta | — | — |
EBITDA | −11,10 mln | −8,28% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (AUD) | dets 2023info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 103,73 mln | 51,71% |
Kogu vara | 123,79 mln | 43,92% |
Kõik kohustused | 8,15 mln | −12,60% |
Kogu omakapital | 115,64 mln | — |
Emiteeritud aktsiate arv | 1,19 mld | — |
Hinna ja väärtuse suhe P/B | 1,83 | — |
Varade tasuvus | −23,35% | — |
Kapitali tasuvus | −24,65% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (AUD) | dets 2023info | Y/Y muutus |
|---|---|---|
Puhastulu | −10,61 mln | −2,93% |
Põhitegevuse rahakäive | −9,23 mln | −54,83% |
Investeeringute raha | −209,56 tuh | −607,90% |
Finantseerimise raha | −215,93 tuh | −278,22% |
Raha ja raha ekvivalentide muutus | −9,84 mln | −69,40% |
Tasuta rahavoog | −6,90 mln | −2,37% |
Teave
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Tegevjuht
Asutatud
2001
Veebisait
Töötajate arv
19
